Introduction: Hyperkalemia (HK), defined as serum potassium (K + ) >5.0 mEq/L, is an independent predictor of mortality in patients on maintenance hemodialysis (HD). This study investigated the annual prevalence of HK and examined patient characteristics potentially associated with a higher annual HK prevalence. Methods: This retrospective observational cohort study used Dialysis Outcomes and Practice Patterns Study (DOPPS) survey data from US patients undergoing in-center HD thrice weekly from 2018 to 2019. The primary endpoint was the proportion of patients with any predialysis HK (K + >5.0 mEq/L) within 1 year from the index date (date of DOPPS enrollment), using the first hyperkalemic K + value. Secondary endpoints were the proportion of patients with moderate-to-severe (K + >5.5 mEq/L) or severe (K + >6.0 mEq/L) HK. Findings: Overall, 9347 patients on HD were included in this analysis (58% male and 49% aged >66 years). Any predialysis HK (K + >5.0 mEq/L) occurred in 74% of patients within 1 year of the index date, 52% within 3 months, and 38% within 1 month. The annual prevalence of moderate-to-severe and severe HK was 43% and 17%, respectively. Recurrent HK (at least two K + >5.0 mEq/L within 1 year) occurred in 60% of patients, and 2.8% of patients were prescribed an oral K + binder. Multivariable logistic regression analysis showed younger age, female sex, Hispanic ethnicity, and renin-angiotensin-aldosterone system inhibitor use were significantly associated with a higher annual prevalence of any predialysis HK, while Black race, obesity, recent initiation of HD, and dialysate K + bath concentration ≥3 mEq/L were associated with a lower prevalence of HK.

Background Population-based estimates of anaemia prevalence in patients with chronic kidney disease (CKD) vary, and data on the prevalence of severe anaemia of CKD are limited. This study examined the prevalence of anaemia and anaemia eligible for erythropoiesis-stimulating agent (ESA) treatment in patients with CKD in the United States (US). Methods National Health and Nutrition Examination Survey (NHANES) data from 1999–2 000 to 2017–2 018 were used to determine the prevalence of diagnosed anaemia (haemoglobin <12 g/dL in women; <13 g/dL in men) and anaemia eligible for ESA treatment (haemoglobin <10 g/dL) in survey participants aged ≥ 18 years with stage 3–5 non-dialysis-dependent CKD (estimated glomerular filtration rate <60 mL/min/1.73 m2). The study objectives were to (1) obtain a more recent estimate of anaemia prevalence in patients with non-dialysis-dependent CKD and (2) examine the characteristics of individuals with CKD and haemoglobin <10 g/dL. Results Of 51 163 eligible NHANES participants, 2 926 (5.7%) with stage 3–5 CKD were included. In all participants, the weighted prevalences of anaemia and haemoglobin <10 g/dL were 25.3% and 1.9%, respectively. Mean haemoglobin levels decreased numerically between 1 999 and 2 012 and remained stable thereafter. The prevalence of anaemia and haemoglobin <10 g/dL increased with advancing CKD stage. The odds of haemoglobin <10 g/dL were significantly higher in stage ≥ 3B versus 3A and in non-Hispanic Blacks versus other races. Conclusions In our analysis, approximately 25% of individuals with stage 3–5 CKD in the US had anaemia and approximately 2% had anaemia eligible for ESA treatment.

No abstract

No abstract